NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.72) by $0.12. The biopharmaceutical company had revenue of $35.44 million for the quarter, compared to analyst estimates of $33.72 million. Agios Pharmaceuticals had a negative return on equity of 77.09% and a negative net margin of 348.96%. The firm's quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.58) earnings per share. View Agios Pharmaceuticals' Earnings History.

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Agios Pharmaceuticals.

11 equities research analysts have issued 1 year price objectives for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $79.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $64.56 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

Press coverage about AGIO stock has trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Agios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), bluebird bio (BLUE), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), NVIDIA (NVDA) and Micron Technology (MU).

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.99%), Capital International Investors (7.70%), State Street Corp (3.20%), First Trust Advisors LP (2.60%), Farallon Capital Management LLC (2.12%) and ArrowMark Colorado Holdings LLC (1.88%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Capital International Inc. CA, Capital Bank & Trust Co, Alliancebernstein L.P., Casdin Capital LLC, Handelsbanken Fonder AB, Capital International Investors and Rhenman & Partners Asset Management AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

AGIO stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Perceptive Advisors LLC, First Trust Advisors LP, Bank of America Corp DE, Marshall Wace LLP, Geode Capital Management LLC, UBS Asset Management Americas Inc. and Cadian Capital Management LP. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, David Scadden and Jacqualyn A Fouse. View Insider Buying and Selling for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $53.68.

Agios Pharmaceuticals has a market capitalization of $3.16 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

The official website for Agios Pharmaceuticals is http://www.agios.com/.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]